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Case Report 
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A 63-year-old female patient presented with a one-week history of reduced appetite, weakness, nausea, polyuria, 
and occasional vomiting on a background of recurrent urinary tract infection and hypothyroidism. She appeared 
lethargic and dehydrated. The arterial blood gas showed a picture of diabetic ketoacidosis (DKA) which was 
treated according to the protocol. Viral polymerase chain reaction (PCR) for COVID-19 was positive. The 
diagnosis of new-onset type one diabetes is made based on specific antibodies test. Computerized Tomography 
(CT) of the abdomen excluded pancreatic cancer as a cause of new-onset diabetes. Hence, the patient was labelled 
as type one diabetes mellitus induced by the COVID-19 virus. She was treated accordingly and sent home on 
insulin. 
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Introduction 
 
The data obtained so far after the onset of the COVID-
19 pandemic showed that the risk of contracting the 
virus by patients with diabetes is the same as the 
patients with non-diabetes.1 However, the patients 
with diabetes are at risk of increased complications 
especially diabetic ketoacidosis thus increasing the 
mortality rate.2 Certain cases of new-onset diabetes in 
patients have been published.3,4 It is still unclear how 
the COVID-19 virus causes new-onset diabetes and its 
complications. It is believed that the likely cause is 
increased expression of angiotensin-converting 
enzyme 2 (ACE-2) receptor which acts as an entry 
point of COVID-19 virus into the pancreatic cells 
leading to the destruction and causing new-onset 
diabetes.5 However, this theory still needs further 
research. 
 
Materials and Methods 
 
A 63 years old female patient presented to the accident 
and emergency department with complaints of 
reduced appetite, weakness, nausea, polyuria, and 
occasional vomiting for a week. The background 
history included recurrent urinary tract infections and 
hypothyroidism. She was taking Levothyroxine 50 
microgram once a day at the time of presentation; was 
self-employed, non-smoker, and consumed alcohol 
socially (4-6 units per week). There was no significant 
family history of note. 
Vitals measurement showed blood pressure of 103/76 
mmHg, a pulse of 92 beats per minute, respiratory rate 
of 17 per minute, oxygen saturation on room air 98%, 
and temperature of 37.9 C. 
On general examination, the patient appeared 
dehydrated and lethargic, and mildly agitated. 
Systemic examination showed normal air entry in both 
lungs, normal heart sounds, and audible bowel 
sounds. 
Arterial blood gas (ABG) was done upon arrival which 
showed pH 7.08, pO2 14.2, pCO2 3.9, HCO3 6.3, 
glucose 37.5, and lactate 2.7; blood ketones of 6.7 were 
recorded. Noticing diabetic ketoacidosis picture, the 
patient was immediately commenced on DKA 
protocol. Serial ABGs were done and electrolytes were 
checked as per protocol. She recovered out of DKA 






Investigations: Laboratory investigations showed C-
reactive protein 15, White cell count 15, Sodium 133, 
Potassium 4.4, Hemoglobin 126 g/dl, Creatinine 151, 
Urea 10.4, and AKI stage 2. Urine dip showed negative 
blood, nitrites, and leukocytes. HBa1c was 10.5%. The 
screening test for SARS-CoV-2 (COVID-19) returned 
positive. 
Chest x-ray report revealed no abnormal findings. An 
electrocardiogram showed sinus rhythm. There was a 
suspicion of pancreatic cancer as a likely cause of new-
onset diabetes. So CT scan of the abdomen was 
arranged which did not show any pancreatic and peri-
pancreatic lesions. 
Antibodies tests for type 1 diabetes mellitus showed 
Glutamic Acid Decarboxylase antibody level of 57 
U/mL (0-10.9U/mL), Insulinoma associated-2 
antibody level of 3461U/mL (0-7.99U/mL) and Zinc 
transporter 8 antibody level of 1443U/mL (0-
9.99U/mL). The antibodies results were consistent 
with type 1 diabetes mellitus and COVID-19 infection 
was considered as the likely cause given normal CT 
pancreas. 
Differential diagnosis: New-onset type one diabetes 
mellitus in middle age patients can be due to 
pancreatic cancer, recent pancreatic trauma or surgery, 
and infection. Our patient has no recent abdominal 
trauma or surgery. The risk of alcoholic-induced 
pancreatic damage was low due to non-heavy intake. 
Pancreatic cancer was ruled out due to normal CT scan 
findings. In the absence of other causes, COVID-19 
infection was considered a likely cause. 
Treatment: DKA protocol was treated according to the 
protocol. Electrolytes and ketones were checked 
regularly and the patient was rehydrated. An opinion 
from consultant endocrinology was taken due to new-
onset diabetes mellitus and the patient was initiated on 
insulin. All necessary guidance about insulin and 
diabetes mellitus was given to the patient. No specific 
treatment was given for COVID-19 infection. 
Outcome and follow-up: The patient was sent home 
after stabilization. A follow-up appointment was 





COVID-19 infection has a wide spectrum of 
complications. Patients with diabetes are at the same 
risk of contracting the virus as patients with no 
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diabetes.9 However, if contracted COVID-19, the 
severity of the disease is high in patients with 
diabetes.6,7 Diabetic ketoacidosis is a serious 
complication of diabetes mellitus. COVID-19 infection 
worsens the outcome and mortality in patients with 
diabetes.7 
The exact mechanism of COVID-19 infection leading to 
new-onset diabetes mellitus or complications in known 
patients with diabetes is still not fully known. 
However, recent studies showed that it can be due to 
overexpression of ACE-2 receptors on pancreatic beta 
cells8 through which the COVID-19 virus gain entry 
into the cells and cause destruction, leading to insulin-
dependent diabetes. 
Studies during the previous coronavirus epidemics 
showed that dipeptidyl peptidase 4 (DPP4) is the 
receptor of entry for Middle East respiratory 
syndrome coronavirus. Hence, it is believed that the 
DPP4 receptor can also act as an entry point. But the 
studies about this relationship are limited. Due to 
serious side effects of DPP4 inhibitor on the immune 
system, COVID-19 infection can worsen the outcome.11 
However, other studies do not support this relation of 
DPP4 inhibitors and weakening of immunity.10 
Sodium/glucose cotransporter 2 inhibitors have been 
shown to worsen the outcomes in patients with 
COVID-19 infections. The exact etiology is unknown. 
However, it is found out that the SGLT2i increase the 





1. The case shows the likely association between 
COVID-19 infection and new-onset type 1 
diabetes mellitus. 
2. COVID-19 infection can precipitate diabetic 
ketoacidosis in a patient with diabetes. 
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